ERBB2 and breast carcinoma: By using more biomarkers such as progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), breast cancer is further divided into several molecular subtypes, such as luminal A, luminal B, basal-like and HER2-positive ones [3,4].